Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares were up 3.1% during trading on Wednesday . The stock traded as high as $47.49 and last traded at $47.13, with a volume of 206,604 shares traded. The stock had previously closed at $45.73.

Several research analysts have recently commented on EGRX shares. Mizuho reissued a “buy” rating and issued a $71.00 target price on shares of Eagle Pharmaceuticals in a report on Friday, May 6th. Royal Bank Of Canada reissued a “buy” rating and issued a $78.00 target price on shares of Eagle Pharmaceuticals in a report on Monday, June 13th. Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 4th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $98.00 target price on shares of Eagle Pharmaceuticals in a report on Thursday, April 7th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $88.94.

The stock’s market cap is $676.26 million. The stock has a 50-day moving average of $43.60 and a 200-day moving average of $50.10.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by $0.52. The firm had revenue of $29.60 million for the quarter, compared to the consensus estimate of $29.07 million. During the same quarter in the previous year, the company earned $1.31 earnings per share. The company’s revenue for the quarter was down 18.5% on a year-over-year basis. On average, analysts expect that Eagle Pharmaceuticals Inc. will post $3.32 earnings per share for the current year.

In other news, major shareholder Proquest Management Llc sold 17,980 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The shares were sold at an average price of $40.72, for a total transaction of $732,145.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several hedge funds and institutional investors have made changes to their positions in the company. Century Capital Management LLC boosted its position in shares of Eagle Pharmaceuticals by 34.4% in the fourth quarter. Century Capital Management LLC now owns 66,209 shares of the specialty pharmaceutical company’s stock valued at $5,871,000 after buying an additional 16,942 shares in the last quarter. Turner Investments L.P. acquired a new position in shares of Eagle Pharmaceuticals during the fourth quarter valued at approximately $2,350,000. Bank of Montreal Can boosted its position in shares of Eagle Pharmaceuticals by 62.3% in the fourth quarter. Bank of Montreal Can now owns 119,902 shares of the specialty pharmaceutical company’s stock valued at $10,632,000 after buying an additional 46,020 shares in the last quarter. OppenheimerFunds Inc. acquired a new position in shares of Eagle Pharmaceuticals during the fourth quarter valued at approximately $6,104,000. Finally, ProShare Advisors LLC acquired a new position in shares of Eagle Pharmaceuticals during the fourth quarter valued at approximately $1,222,000.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.